Molbio Diagnostics Shares Surge 87% From IPO Price in Just 19 Trading Sessions Following Massive 20% Upper Circuit Rally
_1991306876.jpg)
Shares of Molbio Diagnostics Ltd. delivered a spectacular performance on Thursday, September 10, locking in a 20 percent upper circuit to touch Rs 1,509.40 on the stock exchanges. This sharp upward trajectory marks an extraordinary 87 percent surge from the company's initial public offering (IPO) issue price of Rs 807, bringing the stock within striking distance of officially doubling early investors' capital. Having made a strong market debut on August 17 at Rs 980—reflecting an immediate 21.4 percent listing gain—the healthcare stock has sustained relentless buying momentum over just 19 trading sessions, cementing its status as one of the most successful primary market listings of the season.
Record-Breaking IPO Subscription and Institutional Backing
The extraordinary post-listing rally follows a highly successful public issue when Molbio Diagnostics launched its Rs 940 crore IPO, which concluded with an overwhelming 70.26 times overall subscription by August 12. Investor enthusiasm was powered by stellar demand across all categories, with the Qualified Institutional Buyers (QIB) segment witnessing a massive 186.39 times subscription, Non-Institutional Investors (NII) subscribing 49.80 times, and Retail Investors bidding 12.96 times against their reserved allocations. Comprising a fresh issue of Rs 200 crore alongside an Offer for Sale (OFS) of 91.66 lakh shares, the offering also secured strong pre-listing backing of Rs 281.5 crore from prominent anchor investors, including global financial heavyweights like Goldman Sachs, BlackRock Global Funds, and the International Finance Corporation (IFC).
Innovative Point-of-Care Diagnostics and Robust FY26 Financial Growth
Headquartered in Goa, Molbio Diagnostics is a recognized pioneer in developing cutting-edge Point-of-Care Diagnostic Solutions, anchored by its globally patented flagship platform, Truenat. Designed to facilitate decentralized molecular testing with rapid diagnostic results within an hour, the Truenat platform is protected across more than 100 countries and deployed extensively for detecting critical infectious diseases, including Tuberculosis, COVID-19, Hepatitis B and C, HIV, and HPV. The company's stellar stock performance is strongly underpinned by robust financial fundamentals, as Molbio reported a 14.8 percent year-on-year increase in net profit to Rs 166.6 crore and a 41.7 percent surge in revenue to reach Rs 1,445.7 crore for the financial year 2025-26. Looking ahead, the firm plans to channel fresh issue proceeds into strategic expansion and research initiatives, allocating Rs 105.5 crore specifically toward establishing an advanced Research & Development Facility and Centre of Excellence via its subsidiary Bigtec.
_1549465744_351x234.jpg)
_2119425040_351x234.jpg)
_738410885_351x234.jpg)
_1532468312_351x234.jpg)
_2067480648_351x234.jpg)
